Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04782258
Recruitment Status : Not yet recruiting
First Posted : March 4, 2021
Last Update Posted : March 4, 2021
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)

Condition or disease Intervention/treatment Phase
Autosomal Recessive Polycystic Kidney (ARPKD) Drug: Tolvaptan Suspension Drug: Tolvaptan Tablets Phase 3

Detailed Description:

Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 3), a closely related indication to ARPKD, as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV).

The trial will be the first trial of tolvaptan in a pediatric ARPKD population.

Participants in this study will be assigned to tolvaptan for 18 months and closely monitored over the course of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Estimated Study Start Date : April 1, 2021
Estimated Primary Completion Date : March 31, 2025
Estimated Study Completion Date : June 1, 2025


Arm Intervention/treatment
Experimental: Tolvaptan Suspension
Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
Drug: Tolvaptan Suspension
Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.

Experimental: Tolvaptan Tablets
Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later based on weight if able to swallow tablets.
Drug: Tolvaptan Tablets
Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later based on weight if able to swallow tablets. Treatment duration is 18 months.




Primary Outcome Measures :
  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Enrollment up to 7 days post last dose ]

Secondary Outcome Measures :
  1. Rate of change of eGFR (by Schwartz formula) from baseline to post-treatment after 18 months of treatment [ Time Frame: From Enrollment to 18 months ]
  2. The percentage of subjects that will receive renal replacement therapy (RRT) by 18 months. [ Time Frame: From Enrollment to 18 months ]
  3. The amount of time between enrollment and 18 months that a subject requires renal replacement therapy (RRT). [ Time Frame: From enrollment to 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects from Trial 156-12-204 who have completed treatment or male or female subjects between 28 days and less than 18 years of age, who have been diagnosed with a clinical diagnosis of ARPKD.
  2. Ability for parent or guardian to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.
  3. Ability to commit to remain fully abstinent or use two approved methods of birth control.

(periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] or withdrawal are not acceptable methods of contraception) during the trial and for 30 days following the last dose of IMP for sexually active females of childbearing potential.

Exclusion Criteria:

  1. Premature birth (≤ 32 weeks gestational age).
  2. Anuria or RRT.
  3. Evidence of syndromic conditions associated with renal cysts (other than ARPKD).
  4. Abnormal liver function tests including ALT and AST, > 1.2 × ULN.
  5. Has splenomegaly or portal HTN.
  6. Parents with renal cystic disease.
  7. Need for chronic diuretic use.
  8. Cannot be monitored for fluid balance.
  9. Critical electrolyte imbalances, as determined by the investigator.
  10. Has or at risk of having significant hypovolemia as determined by investigator.
  11. Clinically significant anemia, as determined by investigator.
  12. Platelets < 50000 µL.
  13. Severe systolic dysfunction defined as ejection fraction < 14%.
  14. Serum sodium levels < 130 mmol/L.
  15. Cannot be taking any other experimental medications.
  16. Require ventilator support.
  17. Taking medications known to induce CYP3A4.
  18. Having an infection including viral that would require therapy disruptive to IMP dosing.
  19. Females who are breast-feeding or who have a positive pregnancy test result prior to receiving IMP.
  20. Subjects with a history of substance abuse (within the last 6 months).
  21. Subjects who have bladder dysfunction and/or difficulty voiding.
  22. Subjects 12 years of age and older having contraindications to, or interference with MRI assessments (eg, ferro-magnetic prostheses, aneurysm clips, severe claustrophobia).
  23. Subjects taking a vasopressin agonist (eg, desmopressin).
  24. Subjects with a history of persistent noncompliance with antihypertensive or other important medical therapy.
  25. Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (ie, marketed) therapies for the purpose of affecting PKD cysts such as tolvaptan, vasopressin antagonists, anti-sense RNA therapies, rapamycin, sirolimus, everolimus, or somatostatin analogs (ie, octreotide, sandostatin).

CYP = Cytochrome P; HTN = hypertension; RNA = ribonucleic acid; ULN = upper limit of normal


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04782258


Contacts
Layout table for location contacts
Contact: Lindsay Getz (919) 797-9591 Lindsay.Getz@paidion.com

Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Investigators
Layout table for investigator information
Study Director: Rosa Real, MD Rosa.Real@otsuka-us.com
Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT04782258    
Other Study ID Numbers: 156-201-00307
First Posted: March 4, 2021    Key Record Dates
Last Update Posted: March 4, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
ARPKD
TOLVAPTAN
Polycystic Kidney Disease
Autosomal Recessive Polycystic Kidney Disease
Adolescent
Renal Cysts
Oligohydramnios
Anhydramnios
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Recessive
Urologic Diseases
Kidney Diseases, Cystic
Abnormalities, Multiple
Congenital Abnormalities
Ciliopathies
Genetic Diseases, Inborn
Tolvaptan
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs